NR1H4 and metabolic syndrome: FXR agonism by bile acids or synthetic FXR agonists has also been linked with lowered plasma cholesterol levels and decreased hepatic steatosis [16,17], while FXR−/−-mice develop a dysregulated metabolic profile marked by dyslipidemia [18], underlining the physiological role of bile acids in metabolic homeostasis.